Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U
    Session Type: Symposium

    World Urological Oncology Federation (WUOF) Symposium

    Wednesday, October 29, 2025
    07:30 - 17:00 GMT+0

    Meeting Objectives:




    • Highlight Emerging Paradigms in Urologic Cancer Care:
      Explore how novel diagnostics, therapeutics, and care models are transforming management across prostate, bladder, and kidney cancers.


    • Promote Multidisciplinary Collaboration and Translational Research:
      Foster dialogue between urologists, oncologists, and radiation oncologists to accelerate bench-to-bedside innovation.

    Presentations:

    • 07:30 - 07:55 GMT+0
      Meet and Greet International Colleagues
    • 07:55 - 08:00 GMT+0
      Framing of Theme

      Co-Chair: Laurence Klotz – Sunnybrook Research Institute

      Co-Chair: Peter Hammerer – Academic Hospital Braunschweig

    • 08:00 GMT+0
      SESSION ONE | LOCALISED PROSTATE CANCER

      Moderator: Caroline Moore – University College London

    • 08:00 - 08:15 GMT+0
      Update on Screening: MRI For All Men with PSA > 1.0?
    • 08:15 - 08:30 GMT+0
      How Should We Biopsy? - Transperineal vs Transrectal
    • 08:30 - 08:45 GMT+0
      Targeted Only vs Targeted + Systematic

      Speaker: Laurence Klotz – Sunnybrook Research Institute

    • 08:45 - 09:00 GMT+0
      Will Imaging Replace Prostate Biopsy?
    • 09:00 - 09:15 GMT+0
      Lifestyle and Urologic Cancer
    • 09:15 - 09:30 GMT+0
      Update - Risk Stratification of Localized Disease in 2025
    • 09:30 - 09:33 GMT+0
      Case Presentation: 62 Year Old Man With 10% Pattern 4 GG 2
    • 09:33 GMT+0
      The Best Treatment Option Should Be:
    • 09:33 - 09:41 GMT+0
      SURGERY
    • 09:41 - 09:49 GMT+0
      XRT
    • 09:49 - 09:57 GMT+0
      FOCAL
    • 09:57 - 10:05 GMT+0
      AS
    • 10:10 - 10:20 GMT+0
      Discussion & Audience Voting
    • 10:20 GMT+0
      SESSION TWO | KIDNEY
    • 10:20 - 10:35 GMT+0
      Update: Biomarkers and RCC
    • 10:35 - 10:50 GMT+0
      Tips and Tricks for Robotic Partial Nephrectomy
    • 10:50 GMT+0
      Debate: Best Treatment for Localised Kidney Cancer
    • 10:50 - 11:02 GMT+0
      SBRT for RCC: Challenging the Radioresistant Paradigm
    • 11:02 - 11:14 GMT+0
      Surgery Should be the Primary Treatment Modality for Localised Kidney Cancer
    • 11:15 - 11:20 GMT+0
      Discussion & Audience Voting
    • 11:20 - 11:35 GMT+0
      Adjuvant Therapy Post Nephrectomy: Who Should Receive Treatment?
    • 11:35 - 11:50 GMT+0
      Advanced RCC: Update on Systemic Therapy
    • 11:50 - 12:00 GMT+0
      Coffee Break
    • 12:00 GMT+0
      SESSION THREE | SPECIAL GUEST LECTURE

      Moderator: Peter Hammerer – Academic Hospital Braunschweig

    • 12:00 - 12:20 GMT+0
      The Case for Image Guided Management

      Speaker: Mark Emberton – UCL

    • 12:20 - 12:40 GMT+0
      Innovative Design and Real-World Validation: The STAMPEDE Trial for Prostate Cancer

      Speaker: Noel Clarke – University of Manchester

    • 12:40 - 13:00 GMT+0
      AI and Clinical Decision Making in Oncology
    • 13:00 GMT+0
      SESSION FOUR | UROTHELIAL CANCER

      Moderator: Leonardo Reis

    • 13:00 - 13:15 GMT+0
      Biomarkers for Bladder Cancer-Impact on Treatment Decision

      Speaker: Badrinath Konety – Allina Health Cancer Institute, Allina Health System

    • 13:15 - 13:30 GMT+0
      Novel Drug Delivery Systems for Intravesical Treatment
    • 13:30 - 13:45 GMT+0
      IO + BCG for High Risk nmiBC

      Speaker: Leonardo Reis

    • 13:45 - 14:00 GMT+0
      Open vs. Robotic Radical Cystectomy - Does it Matter?

      Speaker: Guram Karazanashvili – Karazanashvili Robotic Center

    • 14:00 - 14:15 GMT+0
      cT0 After Neoadjuvant Therapy in Bladder Cancer: Is Cystectomy Still Required?

      Speaker: Makarand V. Khochikar – KIMS-UAIMS hospital , Sangli India

    • 14:15 - 14:30 GMT+0
      Best Management of Node Positive Disease

      Speaker: Seth Lerner – Baylor College of Medicine

    • 14:30 GMT+0
      Panel Discussion: Stopping Bladder Cancer Before It Starts: What We Know and What’s Next
    • 14:30 - 14:40 GMT+0
      Risk Factors
    • 14:40 - 14:50 GMT+0
      Bladder Cancer Prevention Program Update | A WUOF International Initiative WUOF
    • 14:50 - 15:00 GMT+0
      Discussion & Audience Voting
    • 15:00 - 15:10 GMT+0
      Coffee Break
    • 15:10 GMT+0
      SESSION FIVE| Advanced Prostate Cancer

      Moderator: Vidit Sharma – Mayo Clinic

    • 15:10 - 15:25 GMT+0
      How to Treat Oligometastatic Prostate Cancer: Is there a Role for Radical prostatectomy?
    • 15:25 - 15:40 GMT+0
      Metastasis Directed Therapy: Wishful thinking?
    • 15:40 GMT+0
      Debate: Best Treatment for mHSPC
    • 15:40 - 15:55 GMT+0
      Will PARP Inhibition in HRR Mutated Patients Become the New Standard?

      Speaker: Peter Hammerer – Academic Hospital Braunschweig

    • 15:55 - 16:10 GMT+0
      Doublet Therapy Should be the Treatment of Choice for Most High Risk mHSPC Patients
    • 16:10 - 16:25 GMT+0
      Triplet Therapy Should be Much More Widely Utilised for These Patients
    • 16:25 - 16:30 GMT+0
      Discussion & Audience Voting
    • 16:30 GMT+0
      Debate: Best Treatment for mCRPC
    • 16:30 - 16:45 GMT+0
      PARP-Inhibition + ARPI for Unselected Patients or Only HRR Mutated Patients?

      Speaker: Stefanie Zschäbitz – University Hospital Heidelberg, Germany

    • 16:45 - 17:00 GMT+0
      PSMA-Targeted Radioligand Therapy in Taxan-Naive mCRPC Patients?

      Speaker: Robert Reiter – University of california Los Angeles

    • 17:00 GMT+0
      Concluding Remarks

      Speaker: Peter Hammerer – Academic Hospital Braunschweig